2940nm Er:YAG Laser Versus Benzoyl Peroxide Gel for the Treatment of Inflammatory Acne

Chulalongkorn University

Status: Completed

Conditions: Acne Vulgaris

Treatments: Drug: Benzoyl Peroxide gel; Device: 2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)

Study type: Interventional

Funder types: Other

Identifiers

NCT01472900

ERYAG-AC01

Details and patient eligibility

About

Acne is one of the most common conditions that patients seek for help in dermatological clinic. Nowadays, conventional treatment including topical agents(retinoids, antibiotics ,antiseptics and keratolytic agents) and systemic agents( antibiotics and retinoids) give a satisfying result but not to every patient. Some patients are not well respond to conventional therapy while some patients are unable to tolerate side effects of the treatments. Therefore, interventions to reduce acne are vigorously experimented . Lights and lasers including intense pulsed light, pulsed dye laser with or without photosensitizer and infrared lasers have been found to be useful in treating active inflammatory acne. Although,pain ,downtime and poor response of comedonal acne are limitations of those lights and lasers therapy. 2940 nm Erbium:YAG laser which has both resurfacing and photothermal effects is our laser of interest to seek for its efficacy in the treatment of inflammatory acne.

Enrollment: 25 estimated patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 year-old to 45 year-old
• Mild to moderate severity of acne vulgaris with at least 5 active inflammatory acne lesions on each side of the face and less than 25% difference in lesion count between each side of face
• Fitzpatrick skin phototype I-IV

Exclusion criteria

• History or clinical presentation of hypertrophic scar or keloid
• Photoaggravated skin diseases i.e. systemic lupus erythematosus, polymorphous light eruption, solar urticaria
• Oral isotretinoin taken within the last 6 months prior to enrollment
• Topical retinoid within 4 weeks prior to enrollment
• Systemic acne therapies (oral antibiotics) within 4 week prior to enrollment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

25 participants in 2 patient groups

Er:YAG laser

Experimental group

Treatment:

Device: 2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)

BP gel

Active Comparator group

Treatment:

Drug: Benzoyl Peroxide gel